The court’s action would let Amphastar and Watson enter the market for generic Lovenox, Michael Tong, an analyst with Wells Fargo Securities in New York, said in a note to clients. Parsippany, New Jersey-based Watson would have to begin sales knowing there’s a risk it could later lose the case, Tong said.
“A launch is not necessarily imminent,” he said.
Momenta and Novartis AG (NOVN)’s Sandoz unit already sell a copy of Lovenox, and Momenta won an order in October that prevented Amphastar and Watson from marketing their version. The appeal of that decision was heard by on Jan. 24. The resulting “order does not represent a final decision with respect to the merits of the pending appeal,” the court said in yesterday’s docket.
Ironically all that's changed is the monmentum. MNTA could drag feet gaming the court system with the stay in place. Now that the stay has been lifted it's time for the competition to drag out the proceedings.
You are right this has changed nothing and if they win the right to produce as a competitor they will have to deal with a lot to make that happen. We are talking time and a panic today gave me the chance to buy a very highly rated company at discount. I will pick up more if it goes down more or not.